PDS Biotechnology Corp (PDSB)

[Bertsllc]

PDS Biotech to Host Oncology R&D Day on June 16, 2021

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 – 10:00 AM ET on Wednesday, June 16th.
PDS Biotech’s Oncology R&D Day will focus on the Company’s advancements in its ongoing preclinical and clinical work and will feature presentations from:

Dr. Frank Bedu-Addo, President and CEO, PDS Biotech
Dr. Lauren V. Wood, Chief Medical Officer, PDS Biotech
Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health
Dr. Julius Strauss, Principal Investigator, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health
Dr. Caroline Jochems, Staff Scientist, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institute of Health
A copy of the presentations will be available on June 17th on the scientific presentations and publications page of PDS Biotech's website. Registration for PDS Biotech’s Oncology R&D Day is now open and a live webcast of the event will be available online in the investor relations section of the company's website at https://pdsbiotech.com/investors/news-center/events. A replay will be available on the company website for 90 days following the webcast.